127 results about "Renal Tubular Epithelial Cells" patented technology

The present invention provides a method for screening or identifying therapeutic or prophylactic agents for renal diseases, which comprises assaying a test substance for the activity of up-regulating the expression of fatty acid-binding protein (FABP), and novel mouse proximal renal tubular epithelial cell lines useful therein. The present invention also provides therapeutic or prophylactic agents for renal diseases comprising, as an active ingredient, an agent having activity of up-regulating FABP expression; agents for up-regulating the expression of FABP, and for treating or preventing renal diseases, which comprise a compound having activity of peroxisome proliferator-activated receptor (PPAR) agonist or carnitine palmitoyltransferase (CPT) inhibitor or the like.

The invention relates to the use of human fat-derived mesenchymal stem cells in the treatment of diseases in kidney and ocular fundus. The invention provides the use of the human fat-derived mesenchymal stem cells in cell preparation for treating diseases in kidney and / or ocular fundus, such as acute kidney injury, renal fibrosis, renal tubular epithelial cell damage, retinosis, diabetic retinopathy and retinal tear. The cell preparation can promote the repair of kidney structure and damaged eyeball pathologic structure with good effect.

Glossy ganoderma as a traditional Chinese medicine is called immortal grass since ancient times and known as the ability to treat various diseases; a pair of lingzhiol A optical enantiomers is purified from ganoderma lucidum, and the lingzhiol A optical enantiomers have obvious effects on inhibiting rat renal mesangial cell strains induced by high glucose to generate reactive oxide species, IL-6, fibronectin and IV type collagen, and also can obviously inhibit the phosphorylation of the renal tubular epithelial cell Smad3 induced by TGF-beta1, so that the application prospect of the compound in preparation of medicines for treating diabetic nephropathy and chronic nephropathy is shown.

A bioartificial renal tubule is provided that forms an artificial kidney together with a bioartificial glomerulus suitable for continuous hemofiltration. The bioartificial renal tubule includes an artificial membrane having an inner surface coated with renal tubular epithelial cells and a vessel containing the artificial membrane. The cells are prevented by the use of a MEK inhibitor from being stratified and therefore form a confluent monolayer on the artificial membrane. The renal tubular epithelial cells are characterized in that the contact inhibition thereof is maintained by the use of the MEK inhibitor. The MEK inhibitor is preferably U0126. The attachment of cells capable of reproducing the function of a kidney allows dialysis to be continuously performed for 24 hours with high efficiency and also allows the ability of a renal tubule to reabsorb useful substances to be achieved.

The invention relates to a traditional Chinese medicinal compositional medicine for treating contrast-induced nephropathy (CIN), which is prepared from the following raw medicinal materials in parts by weight: 1-3 parts of prepared Radix Et Rhizoma Rhei and 1 parts of Ligusticum chuanxiong. The invention also provides application of the traditional Chinese medicinal compositional medicine. The compositional medicine of the invention has the advantages that the formulation of the traditional Chinese medicinal compositional medicine of the invention meets the traditional Chinese medicinal principle of assistant and guide; through the confirmation of pharmacodynamics experiments, the renal function of CIN model rat can be effectively protected, and the effect of controlling CIN is shown; mechanism study finds that the renal function of the rat can be protected by inhibiting the expression of caspase3 and then antagonizing apoptosis of rat renal tubular epithelial cells; and the compositional medicine has fewer number of bulk pharmaceutical chemicals, low toxic adverse effects and low cost, and is suitable for long-term administration. The new traditional Chinese medicinal composition for treating CIN is provided by the invention, and has good application prospects.

The invention provides application of N6-(2-ethoxy)adenosine in preparation of preparations for treating renal failure. By virtue of the N6-(2-ethoxy) adenosine, levels of inosine and urea nitrogen in renal failure and renal ischemia reperfusion injury can be obviously reduced, and renal tubular epithelial cell apoptosis and kidney inflammations are inhibited. The N6-(2-ethoxy) adenosine can be applied to multiple treatment applications of renal failure, renal transplant, renal ischemia reperfusion injury, kidney stone lithotripsy inflammations and other nephritides.

The invention provides a new purpose of a DNA tetrahedron in preparation of a medicine capable of treating renal injury, and belongs to the field of nucleic acid medicines. The invention proves that the DNA tetrahedron can repair injured renal tubular epithelial cells, and discloses the new purpose of the DNA tetrahedron used for treating the renal injury. Since the DNA tetrahedron has high biocompatibility and few medicines used for treating the renal injury are in the presence at present, the new purpose disclosed by the invention has a good application value.

The invention discloses a convolutional neural network-based kidney tubule epithelial cell automatic detection method and belongs to the image processing field. According to the convolutional neural network-based kidney tubule epithelial cell automatic detection method, cells are screened initially based on the morphological features of kidney tubule epithelial cells; identification is carried out based on a convolutional neural network; and therefore, automatic detection of the kidney tubule epithelial cells can be realized, and defects such as low detection efficiency and susceptibility to subjective factors can be avoided, and efficient and convenient detection can be realized. The number of visible components in medical microscopic images is large, and the backgrounds of the medical microscopic images are complex, and as a result, medical personnel tend to generate visual fatigue in a long-term high-intensity working condition, and the possibility of misjudgment or omitted judgment in microscopic examination is large. According to the convolutional neural network-based kidney tubule epithelial cell automatic detection method of the invention, the automatic detection of the kidney tubule epithelial cells can be realized based on digital image processing technologies, and therefore, detection accuracy can be improved, the risk of treatment delay of patients can be lowered, and the labor intensity of the medical personnel can be reduced.

The invention relates to a short peptide having a kidney protection function as well as a preparation method and application thereof. The short peptide having the kidney protection function is characterized in that the amino acid sequence of the short peptide is QEQLERALNSS. The preparation method is characterized by comprising the following steps: successively coupling Ser, Asn, Leu, Ala, Arg, Glu, Leu, Gln, Glu and Gln on serine which is based on resin as a vector; after cracking, and settling with ice ether so as to obtain coarse peptide; and purifying with a high performance liquid chromatography (HPLC) so as to obtain the product. The invention also discloses application of the short peptide having the kidney protection function in the aspects of preparing formulations for treating renal ischemia-reperfusion injury along with acute tubular necrosis, local renal tissue inflammation and renal tubular epithelium cell apoptosis which are caused by the renal ischemia-reperfusion injury. The invention provides a novel clinic medicament for preventing and treating the renal ischemia-reperfusion injury, thereby bringing good news for patients suffering renal transplant.

The invention belongs to the field of pharmacotherapeutics, and particularly relates to application of 18 beta-glycyrrhetinic acid (or salt) for serving as an auxiliary treating drug capable of easing acute kidney injury caused by a chemotherapeutic drug, namely cis-platinum, wherein the 18 beta-glycyrrhetinic acid (or salt) is one of the main components of liquorice. The cis-platinum serves as a commonly-used chemotherapy drug, and clinical application thereof is restricted by kidney toxicity thereof. The levels of creatinine and urea nitrogen in the acute kidney injury induced by the cis-platinum can be inhibited by the18 beta-glycyrrhetinic acid, expression of KIM-1 injured protein is lowered, and apoptosis of renal tubular epithelial cells caused by the cis-platinum is inhibited. According to the application of the 18 beta-glycyrrhetinic acid (or salt) for serving as the auxiliary treating drug capable of easing the acute kidney injury caused by the chemotherapeutic drug, namely the cis-platinum, the effect that the 18 beta-glycyrrhetinic acid has a protecting effect on the acute kidney injury caused by the cis-platinum is discovered for the first time, a mechanism of the 18 beta-glycyrrhetinic acid is related to inhibiting of apoptosis of the renal tubular epithelial cells, and a novel potential drug is provided for Chinese medicine anti-cancer adjuvant therapy.

The invention discloses use of NSC228155 in the preparation of a medicine for preventing and treating acute kidney injury, and particularly relates to application of NSC228155 for treating acute renalinjury by protecting renal tubular epithelial cells. NSC228155 can improve the renal function of a cis-platinum-induced acute kidney injury mouse model, improve the pathological changes of acute renal tubular injury, reduce the apoptosis of mouse kidney tissue, reduce the inflammatory response of kidney tissue, and improve the cis-platinum-induced mitochondrial function and oxidative stress status of the mouse renal cortex tissues and renal tubular epithelial cells and protect renal tubular epithelial cells.

A method for enhancing repair of damaged mammalian tubular epithelial cells involves delivering to the tubular epithelial cells of a subject in need thereof a composition comprising an adeno-associated virus (AAV) comprising an AAV capsid having an amino acid sequence of a selected AAV serotype, and a minigene having AAV inverted terminal repeats and a Sec10 gene operatively linked to regulatory sequences that direct expression of Sec10 in the epithelial cells. In one embodiment, delivery is accomplished by retrograde intrauretal injection. In an embodiment the AAV vector includes a capsid of AAV serotype 2 / 8. Therapeutic compositions containing such AAV are provided.

The effects of hepcidin treatment on mitigating IRI and acute kidney injury by decreasing iron availability and ROS-mediated cell death were tested. C57Bl / 6 (WT) and hepcidin knock out (Hamp− / −) mice were treated with saline or 50 μg of hepcidin i.p. prior to bilateral renal IRI. Renal function, injury markers, histopathology, and inflammation were examined after 24 hours of reperfusion. In WT mice, IRI induced increases in serum and kidney non-heme iron levels, but hepcidin treatment induced sequestration of iron in the spleen and liver and prevented IRI-associated increases in serum and kidney non-heme iron. Kidney function was significantly better in hepcidin-treated mice, accompanied by less acute tubular necrosis and reduced infiltration of immune cells. Hepcidin treatment decreased kidney ferroportin expression and induced the expression of cytoprotectant, H-Ferritin, and was associated with less ROS and tubular epithelial apoptosis. These results demonstrate a protective role of hepcidin in IRI and AKI.

An object of the present invention is to provide a kidney-targeting drug delivery agent which is composed of bioabsorbable materials, transiently accumulates in a kidney and particularly kidney functional units such as tubular epithelial cells for a short period of time, and does not remain in the kidney for a prolonged time after accumulation. The present invention provides a kidney-targeting drug delivery agent which comprises a gelatin-like protein.

The invention discloses the application of dioscin to the preparation of a renal injury protection medicament. Dioscin has a renal injury protection effect, and can be used for preparing the renal injury protection medicament. Dioscin has an obvious lowering effect on NO (Nitric Oxide), TNOS (Total Nitric Oxide Synthase), iNOS (Inducible Nitric Oxide Synthase), MDA (Malondialdehyde), BUN (Blood Urea Nitrogen) and SCr (Serum Creatinine) rise caused by renal injury, has an obvious increasing effect on the reduction of SOD (Superoxide Dismutase), GSH (Glutathione), GSH-Px (Glutathione Peroxidase) and CAT (Catalase) relative to a Model group, and is dose-dependent. After the intervention of dioscin, the phenomena of large-area renal tubular epithelial cell swelling, brush border disappearance, degenerative necrosis of a part of epithelial cells, blockage of lumens by necrotic and exfoliative cellular debris and the like, which are caused by renal injury are obviously alleviated. Dioscin can be used for preparing a medicinal preparation as an active ingredient according to clinical medication needs. Dioscin has the advantages of safety (no toxic or side effects), effectivity, economy, practicability and the like.

The invention provides Ganolactone D (1), a pharmaceutical composition thereof and application of the ganolactone D in pharmacy and foods. The novel compound Ganolactone D is separated from ganoderma lucidum. Researches show that the Ganolactone D can restrain the expression of TGF-beta1 mediated renal tubular epithelial cell alpha-SMA, fibronectin and I-form collagen, thereby indicating that the Ganolactone D can obviously restrain the fibrosis of kidney tissues; and the researches also find that the Ganolactone D can selectively restrain the phosphorylation of TGF-beta1 mediated renal tubular epithelial cell Smad3, but has no obvious influence on the phosphorylation of Smad2, PI3K, ERK and p-38 and the protein expression of Smad4 and Smad7, and the phosphorylation of Smad3 is a common signal path mediating the fibrosis of multiple organs, thereby indicating the treatment effect of the Ganolactone D on the fibrosis of the organs including kidneys.

The invention discloses an application of KD025 in preparation of drugs for preventing and treating chronic renal fibrosis, and especially relates to an application of KD025 in preparation of drugs for resistance of inflammation and protection of renal tubular epithelial cells. KD025 can alleviate the pathological changes of a mice model with chronic renal interstitial fibrosis, reduce the expression level of fibrosis factors in mice kidney tissues, reduce inflammatory reaction of kidney tissues and macrophages, protect the renal tubular epithelial cells in the fibrosis model and reverse transdifferentiation.

The invention discloses an establishment method of a renal aging model. The establishment method comprises the following steps: (1), culturing rat renal tubular epithelial cells in an FBS containing DMEM (dulbecco's modified eagle medium) culture medium at 37 DEG C in presence of CO2 with the concentration of 5%, and after growing to 85-90%, performing subculture according to a ratio of 1:4, wherein cells of each generation are kept and cryopreserved; taking 9th-generation logarithmic phase cells, adjusting the cell concentration to (1-5)*10<4> mL<-1>, and then adding into a 96-mesh plate; (2), adding 10-20 mg.mL<-1> of D-galactose into the 96-mesh plate, and culturing for 24-48 hours to obtain the renal aging model. Experimental results show that the SOD and GSH-PX activities of cells inan induction group have a time-dependent change along with the MDA content under the action of the D-galactose, the SOD and GSH-PX activities gradually decrease and the MDA content gradually increases; the renal aging model established according to the establishment method provided by the invention can be used for screening medicines for preventing and treating renal aging or failure and is of great significance.

The invention relates to ganoderma cochlear phenols A and B, pharmaceutical compositions of ganoderma cochlear phenols A and B and applications of ganoderma cochlear phenols A and B and the pharmaceutical compositions thereof in preparation of medicines and food. Two racemates are separated from ganoderma cochlear and identified, and then the two racemates are split into two pairs of optical enantiomers which are named as levorotatory or dextrorotatory ganoderma cochlear phenols A and B respectively. Researches show that both the racemates and the enantiomers are capable of significantly inhibiting TGF-beta1-induced renal tubular epithelial cell from generating fibronectin, I type collagen and alpha-smooth muscle actin (alpha-SMA), and researches further find that both the racemates and the enantiomers are capable of significantly inhibiting the TGF-beta1-induced renal tubular epithelial cell Smad3 from phosphorylation, which means that the compounds have application prospects in the field of preparation of medicines for resisting renal fibrosis and chronic nephrosis.

The invention relates to a hyperuricemia cell model, a building method thereof and an application of the model to uric acid reduction efficacy evaluation. The building method includes the steps: (1) taking human proximal tubular epithelial cells (HK-2 cells) as model making cells, dissociating the HK-2 cells in a logarithmic phase to prepare cell suspension, adjusting cell density and culturing the cells in a cell culture box for 12-36 hours after planking; (2) removing cell supernatant, cleaning the cells with PBS (phosphate buffer solution) for 2-3 times, adding adenosine and continuing incubation for 12-36 hours; (3) adding xanthine oxidase into the cell supernatant, continuing culture for 12-36 hours, taking out the cell supernatant, and performing efficient liquid detection of uric acid content. Experimental results indicate that the hyperuricemia cell model can be obtained by the aid of the inductor adenosine and the xanthine oxidase. The hyperuricemia cell model is built for the first time, uric acid reduction efficacy of a medicine can be simply and rapidly analyzed, and the model is of great significance for gout medicine research.

The invention relates to a preparation method of tripterine-loaded pH-sensitive lutein-chitosan nano-micelles, which can effectively solve the problems of low bioavailability of LU and Cel and reduction of toxicity of Cel to important organs such as heart, liver and nervous system, and adopts the technical scheme that the tripterine-loaded pH-sensitive lutein-chitosan nano-micelles can be used for preparing the tripterine-loaded pH-sensitive lutein-chitosan nano-micelles. The specific preparation method comprises the following steps: (1) synthesizing a covalent coupling compound of the pH response auxiliary material and the xanthophyll; (2) preparing a lutein-chitosan polymer which is sensitive to pH (Potential of Hydrogen); 3) preparation of the pH-sensitive lutein-chitosan nano delivery system loaded with the tripterine, the preparation method is simple, the prepared pH-sensitive lutein-chitosan nano delivery system loaded with the tripterine can effectively respond to the acid environment of lysosome in renal tubular epithelial cells, the lutein and the tripterine are released, and the delivery effect is good. Kidney inflammation microenvironment can be rapidly improved, AKI can be improved, and the traditional Chinese medicine composition is an innovation of pharmaceutical preparations for treating AKI.

The invention relates to a compound recipe kidney-strengthening tablet for enlivening the spleen and strengthening kidney in the traditional technique field. The preparing method comprises the following steps: disintegrating rhubarb horsetails into the powder; collating after immersing; collecting the collation liquid; disintegrating radix salvia miltiorrhiza, astragalus root, extractum glycyrrhizae liquidum and hirudo into the powder; extracting with alcohol reflux; filtering; merging the filtering liquid and the collation liquid; mixing uniformly; concentrating into the dense plaster; getting the extract of five tastes medicine; adding fermenting Cordyceps sinensis bacterial powder, crystalline cellulose, sodium carboxymethylstarch, starch and dolomol; mixing uniformly; getting the product by pelleting. The invention can reduce BUN and SCr level, which improves plasma protein content, improves the nutrient state, accelerates the renovation and the reactivation of nephric tubule epithelial cell, corrects the metabolic disorder of amino acid, protein and lipid, adjusts the cell immunity, improves the immunity, protects and recovers the kidney function, and prevents secondary infection.

The invention belongs to the field of biological medicines, and relates to an application of baicalin in preparation of a medicine for preventing and / or treating asymptomatic hyperuricemia and / or uricacid nephropathy. Based on animal and cell experiments, the effect of baicalin on hyperuricemia nephropathy is studied, and the result shows that baicalin can inhibit the activity of xanthine oxidase, inhibit uric acid generation, reduce the serum uric acid level of mice with uric acid nephropathy and remarkably improve the renal function of the mice. The baicalin inhibits damage of sodium uratecrystals to rat renal tubular epithelial cells by reducing secretion of TNF alpha, IL-1beta, lactate dehydrogenase and NO.

The invention discloses application of microvesicles from bone marrow mesenchymal stem cells (MSCs) in preparing a drug for treating a kidney injury. According to the application, a recovery effect of the MVs (microvesicles) in a kidney fibration process is verified by in vivo experiments and in vitro experiments. Fibration of renal tubular epithelial cells is caused by TGF-beta1 in the in vitro experiments, the research indicates that the extends of a cell fibration lesion and a cell injury in an MV group are obviously reduced, a unilateral ureteral occlusion animal model is built, the research indicates that in an UUO (unilateral ureteral occlusion) mouse model, average levels of SCr (serum creatinine ), blood UA ( uric acid), urinary protein of an UUO mouse injected with the MVs fall remarkably, the further pathological observation indicates that the extent of the kidney tissue injury of the mouse is improved obviously, the extends of renal mesenchymal fibration, lymphocyte infiltration and renal tubular swelling and necrosis are reduced obviously, and the kidney histopathology grade falls remarkably. That the MSC-MVs have a kidney injury recovery effect on the mouse with the unilateral ureteral occlusion is proved.

The invention discloses a method for inducing differentiation of umbilical cord mesenchymal stem cells toward renal tubular epithelial cells. The method comprises the following steps: culturing umbilical cord mesenchymal stem cells by an induction medium, wherein the induction medium is an LG-DMEM medium and contains FBS with final volume fraction of (8-12)%, RA with final concentration of 10<-8>-10<-6> M, EGF with final concentration of 9-11 ng / mL, penicillin with final concentration of 90-110 U / mL, streptomycin with final cocnnetration of 90-110 U / mL and a UB cell condition medium with finalvolume fraction of (8-12)%. Efficient induction of differentiation of umbilical cord mesenchymal stem cells toward renal tubular epithelial cells in vitro is realized, and cell donors are provided for cell therapy of kidney diseases.

The invention discloses a dialysis membrane material having a physiological function and a preparation method for the same. According to the invention, a TiO2 nanotube array film permeable at two ends is used as a substrate, and renal tubular epithelial cells and umbilical vein endothelial cells are mixedly planted on the film so as to endow the film with a physiology function. The TiO2 nanotube array film is applied in dialysis membrane materials for the first time; since the TiO2 nanotube array film has good blood compatibility, photocatalysis, hydrophilicity and self-cleaning capability, disadvantages of conventional polysulfone membranes are overcome, and requirements for membrane materials for hemodialyzers are well met. The dialysis membrane material having the physiological function prepared by the method can fulfill the functions of kidney tubules and glomerulus, enables an apparatus to be simplified and is favorable for construction of miniaturized biological artificial kidneys. The material is widely used in biomedical fields, e.g., separation of proteins, bioactive filtration, diffusion of high-molecular weight substances, filtration of molecules, conveying of drugs, etc.

The invention discloses application of NSC228155 in treating chronic renal interstitial fibrosis, and particularly relates to application of the NSC228155 in treating the chronic renal interstitial fibrosis by resisting inflammation and protecting renal tubular epithelial cells (RTECs). The NSC228155 can relieve pathological change of a chronic renal interstitial fibrosis mouse model, reduce the expression level of fibrosis factors of renal tissue of a mouse, reduce inflammatory reaction of renal tissue and fibroblasts, protect the RTECs in the fibrosis model and reverse the transdifferentiation effect of the RTECs.